Avaleht › Müelofibroos › Kansas
Müelofibroos kliinilised uuringud osariigis Kansas
6 uuringut haiguse Müelofibroos jaoks otsivad osalejaid osariigis Kansas.
Ametlik uuringutekst (inglise keeles)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- ja veel 1
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. sept 2026 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
VärbamineVarajane 1. faasTerved vabatahtlikud oodatud
Vanused 18 ja vanemad · Kõik sood · Uuendatud 6. mai 2026 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. apr 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
VärbamineFaas 2
Vanused 18–66 · Kõik sood · Uuendatud 17. märts 2026 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2025 · NCT06479135Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.